TRT and erectile dysfunction is one of the most common clinical questions in men's hormone health. Testosterone replacement therapy may improve erectile function in men with confirmed hypogonadism, but it is not a universal treatment for erection problems. Most cases of erectile dysfunction stem from vascular causes, not hormonal deficiency (Mikhail, 2006), meaning low testosterone is only one of several possible contributing factors (Mulhall et al., 2018). The distinction matters because treatment sequencing depends on what is actually driving the problem.

Men considering hormone therapy options should understand that erectile dysfunction and low testosterone are separate conditions that can overlap. A clinical evaluation including testosterone testing and symptom assessment helps determine whether TRT may be appropriate or whether other paths should come first.

How Does Testosterone Affect Erectile Function?

Testosterone contributes to sexual desire and, to a lesser degree, the physiological process of achieving an erection. It supports nitric oxide signaling in penile vascular tissue, which contributes to blood flow and tumescence (Mikhail, 2006). When testosterone drops below levels needed for these pathways, both libido and erectile function may decline.

A 2017 review reported that testosterone therapy may improve mild erectile dysfunction in hypogonadal men, though the effect was less pronounced in more severe cases (Rizk et al., 2017). The AUA guideline notes that testosterone deficiency requires both confirmed low serum testosterone on two separate early-morning measurements and the presence of signs or symptoms (Mulhall et al., 2018). A single blood draw doesn't tell the full story. Conditions like estradiol imbalance and high sex hormone-binding globulin (SHBG) can alter the relationship between total and free testosterone.

Testosterone therapy is generally not indicated for erectile dysfunction when testosterone levels fall within normal range. A meta-analysis of 16 trials found that roughly 65% of hypogonadal men reported improvement in erectile function on testosterone therapy, compared with about 17% on placebo (Mikhail, 2006). That's a meaningful difference, but it also means about one-third of hypogonadal men did not respond.

PDE-5 Inhibitors as First-Line Treatment

For most men with erectile dysfunction, PDE-5 inhibitors (such as sildenafil or tadalafil) remain the standard first-line pharmacological therapy. These medications work by inhibiting phosphodiesterase type 5, which increases cyclic GMP and promotes smooth muscle relaxation in penile tissue. The result is improved blood flow during sexual stimulation.

PDE-5 inhibitors tend to produce faster and more reliable erectile responses than testosterone therapy. They often work independent of testosterone status, which is why providers may prescribe them before ordering hormone labs. Approximately one-third of men do not respond to PDE-5 inhibitors (Mikhail, 2006), prompting evaluation of hormonal factors in non-responders.

Does Combining TRT With PDE-5 Inhibitors Help?

A randomized, placebo-controlled trial of 140 men with low testosterone and erectile dysfunction tested whether adding testosterone gel to sildenafil improved outcomes. No additional benefit was observed. Erectile function, libido, and sexual activity scores showed no meaningful difference between the testosterone-plus-sildenafil group and the placebo group (Spitzer et al., 2012).

PDE-5 inhibitors likely produce such a strong vascular effect that testosterone has little room to contribute once blood flow is already increased. For men already responding to a PDE-5 inhibitor, adding TRT may not measurably improve erection quality. It may still address other symptoms associated with low testosterone like reduced libido, fatigue, and decreased energy.

TRT may, however, make PDE-5 inhibitors work better in men who previously failed to respond. The same review noted that testosterone therapy could improve erectile response to PDE-5 inhibitors specifically in men with mild ED and confirmed low testosterone (Rizk et al., 2017).

A Clinical Approach to TRT and Erectile Dysfunction

Erectile dysfunction is increasingly recognized as a systemic condition with cardiovascular implications. Endothelial dysfunction, the same process that underlies atherosclerosis, is a recognized contributing factor in ED. This makes erectile difficulty a potential early marker of broader vascular disease.

A structured clinical approach starts with evaluation, not a prescription. The Endocrine Society recommends testing testosterone in men with ED and other suggestive symptoms such as reduced libido, fatigue, or loss of lean mass (Bhasin et al., 2018). If total testosterone is confirmed low on repeated morning measurements, testosterone therapy may be appropriate as part of a provider-directed plan.

Men considering TRT should also understand its safety profile. The TRAVERSE trial found no meaningful increase in major adverse cardiovascular events with testosterone therapy compared to placebo. The FDA removed the prior cardiovascular boxed warning in its February 2025 labeling update but added a new blood-pressure warning and retained the limitation of use for age-related hypogonadism (FDA, 2025; Lincoff et al., 2023). A higher incidence of atrial fibrillation, pulmonary embolism, and acute kidney injury was observed in the testosterone group. Hematocrit, blood pressure, and PSA monitoring remain standard during therapy.

Testosterone therapy also suppresses spermatogenesis. Men with fertility goals should discuss this with their provider before starting TRT, because the effect on sperm production is variable and not always fully reversible.

Disclaimer: This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine.

FAQs

Can TRT help with erectile dysfunction?

In men with confirmed hypogonadism, testosterone replacement therapy may improve erectile function. A meta-analysis of 16 trials found that approximately 65% of hypogonadal men reported improvement on testosterone therapy compared to about 17% on placebo (Mikhail, 2006). TRT is less likely to help when erectile dysfunction is caused by vascular disease, nerve damage, or other non-hormonal factors.

Should men with ED get their testosterone tested?

The Endocrine Society and AUA both recommend testosterone testing in men with erectile dysfunction who also have symptoms like reduced libido, fatigue, or decreased lean mass (Bhasin et al., 2018). Proper evaluation requires two separate early-morning blood draws along with a clinical assessment of symptoms.

Does low testosterone cause erectile dysfunction?

Low testosterone is one possible contributing factor, but most cases of erectile dysfunction are vascular in origin. Hypogonadism is found in a relatively small percentage of men presenting with ED. When it is present, treatment of the hormonal deficiency may support erectile function alongside improvements in libido and energy. A provider evaluation helps identify the specific factors involved.

Is it safe to combine TRT with PDE-5 inhibitors?

A randomized trial of 140 men found that adding testosterone gel to sildenafil did not improve erectile outcomes beyond sildenafil alone (Spitzer et al., 2012). Combining these therapies is generally considered safe under provider supervision, but the combination may not produce additional erectile benefits in men who already respond to a PDE-5 inhibitor.

Does TRT and erectile dysfunction treatment affect fertility?

Testosterone therapy suppresses sperm production. The AUA recommends against exogenous testosterone in men actively trying to conceive (Mulhall et al., 2018). This suppression is variable and may not fully reverse after stopping therapy. Men with fertility goals should discuss alternatives with their provider before starting TRT.

What are the cardiovascular risks of TRT?

The TRAVERSE trial, the largest cardiovascular safety trial of testosterone therapy, found no meaningful increase in major adverse cardiovascular events. The FDA's February 2025 labeling update removed the prior boxed cardiovascular warning but added a blood-pressure warning and noted a higher incidence of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group (FDA, 2025; Lincoff et al., 2023).

References

• J Urol. 2018;200(2):423-432

• J Clin Endocrinol Metab. 2018;103(5):1715-1744

• Am J Med. 2006;119(5):373-382

• Curr Opin Urol. 2017;27(6):511-515

• Ann Intern Med. 2012;157(10):681-691

• N Engl J Med. 2023;389(2):107-117

• FDA Drug Alerts and Statements. February 28, 2025